Introduction {#s0005}
============

Platelet-derived growth factor (PDGF) was first isolated from platelet extracts in the early 1970s and classified as a mitogen for fibroblasts and cells of mesenchymal origin.[@b0005] The α granules of platelets are known to be a major storage site for PDGF; however, recent studies have also shown presence of PDGF in several other cell types. Mice studies have highlighted the essential role of PDGF in the early development of the embryo, with a deficiency resulting in defective formation of the lungs, vessels, placenta, brain, and skeleton. In these organs, cell types such as mesangial cells, pericytes, fibroblasts, and glial cells were shown to be dependent on PDGF.[@b0010]

The PDGF family consists of four ligands: A, B, C and D. They function as homodimers with the exception of ligand "AB", which acts as a heterodimer.[@b0015] All four PDGF ligands bind two structurally related tyrosine kinase cell surface receptors, α and β,[@b0020] which relay the message internally and initiate signal induction via Ras and phosphatidylinositol-II pathways. These pathways are essential for PDGF-induced cell migration and mitogenesis, respectively.[@b0025] PDGF-AA, -AB, -BB and -CC activate the PDGF receptor-α (PDGFRα) while PDGF-BB and -DD bind to PDGFRβ ([Fig. 1](#f0005){ref-type="fig"}). PDGF-A is expressed by neurons and astrocytes[@b0030] and, together with PDGFRα, is responsible for recruitment and subsequent development of astrocyte precursors in the retina.[@b0030], [@b0035] PDGF-C plays a critical role in neuronal survival and prevention from apoptosis via regulation of expression of the glycogen synthase kinase 3β.[@b0040] In animal models, eyes treated with PDGF showed decreased retinal pigment epithelial and photoreceptor degeneration.[@b0045] Pericytes express PDGFRβ, allowing PDGF-BB and PDGFRβ to play an important role in the maintenance of retinal vasculature.[@b0050], [@b0055]

PDGF over-activity has also been linked with several systemic conditions including autocrine stimulation of various cells in tumors, atherosclerosis, and fibrotic conditions such as lung, liver, and kidney fibrosis.[@b0060] In fact, PDGF antagonists are currently being evaluated for the treatment of pulmonary hypertension [@b0065] and several different tumors.[@b0070], [@b0075], [@b0080]

Methodology {#s0030}
===========

A systematic search of literature was conducted on PubMed, Scopus, and Google Scholar with no limitation on language or year of publication. Words searched included PDGF, Platelet Derived Growth Factor, PDGF AND antagonist, PDGF AND retinal diseases, PDGF AND AMD, PDGF AND DME, PDGF AND retinal vascular diseases.

PDGF and retinochoroidal vascular diseases {#s0010}
==========================================

A common feature of most retinochoroidal diseases is some degree of vascular insult that leads to ischemia. Such injury consequently leads to release of a wide range of factors that alter the course of the disease process. It was first postulated in 1948 that an angiogenic factor was responsible for retinal neovascularization (NV).[@b0085] Since then, several other key factors have been identified for their critical role in the disease process. Hypoxia inducible factor-1 (HIF-1) was identified as a transcription factor that mediates increased expression of several genes associated with NV. These genes lead to the increased transcription of several key factors that are eventually responsible for new vessel formation; these include vascular endothelial growth factor (VEGF), PDGF, stromal derived growth factor-1 (SDF-1), and placental growth factor (PIGF).

Angiogenesis is considered to consist of five basic steps ([Fig. 2](#f0010){ref-type="fig"}) that include degradation of basement membranes, migration of endothelial cells, tube formation by endothelial cells, new basement membrane formation and finally, encirclement by pericytes for stabilization. In-vitro studies have demonstrated the role of PDGF in the angiogenesis process.[@b0090] It has been shown to promote migration and proliferation of endothelial cells along with an increase in the recruitment of pericytes. These findings, therefore, suggest that PDGF plays a key role in the angiogenesis cascade.

High glucose levels have been shown in-vitro to lead to increased expression of PDGF-β, and therefore, an increase in its binding to PDGF-BB.[@b0095] This glucose-related increased expression was seen in mesangial cells, endothelial cells, and macrophages. Mice studies have shown that retina-specific expression of PDGF-B leads to severe NV and retinal detachment.[@b0100] Similar migratory and proliferative effects of PDGF have also been documented in rabbits.[@b0105] A study conducted by Freyberger et al. reported that PDGF levels were raised in both diabetic and non-diabetic proliferative retinopathy.[@b0110] According to Robbins et al, PDGF-A staining was limited to vessels in the normal retina and choroid, whereas in the diseased retina and choroid, the staining was widespread in the cytoplasm of cells such as macrophages, RPE cells, and fibroblast-like cells. Similarly, unlike normal RPE cells, RPE cells within NV membranes stained strongly positive for PDGF-B receptors, suggesting increased concentrations of both ligands and receptors in such conditions.[@b0115] Therefore, it might be postulated that PDGF, together with other growth factors, plays an integral part in the NV process found in diabetic eyes.

One possible explanation for the involvement of PDGF in the NV process includes entry of platelets and monocytes into the vitreous and subretinal space upon injury to the blood-retina barrier, with subsequent platelet aggregation and PDGF discharge. Interleukins such as IL-1 and TGF-B, released from activated macrophages may lead to further synthesis of PDGF.

Studies evaluating the role of anti-PDGF agents in retinochoroidal vascular diseases {#s0015}
====================================================================================

Several treatment strategies for retinochoroidal vascular diseases have been aimed at blocking the effects of PDGF in the angiogenesis process.

In a mice study, Dong et al. tested the effect of a designed ankyrin repeat protein (DARPin) that selectively binds to and antagonizes PDGF-BB in subretinal NV; the effect was compared to a similar protein that antagonized VEGF-A. According to the study, intra-peritoneal injection of 10 mg/kg of the anti-PDGF protein or 1 mg/kg of the anti-VEGF protein significantly suppressed subretinal NV.[@b0120] The effect of injection of 1 mg/kg anti PDGF-DARPin was not significant; however, when combined with 1 mg/kg anti-VEGF-A DARPin, the suppression was greater than that achieved by the anti-VEGF-DARPin alone. Similarly, strong suppression of retinal NV was also achieved with 1.85 μg of anti-PDGF-BB DARPin. These findings suggest that PDGF is a valid target for the treatment of ocular NV.

Several clinical trials evaluating the role of PDGF antagonists in human eyes are currently ongoing ([Table 1](#t0005){ref-type="table"}). These studies are looking at the safety profile of the available PDGF antagonists as well as their efficacy in comparison with and in combination with other currently available VEGF antagonists.

Ophthotech (New York, U.S.A.) developed a high affinity PDGF antagonist called E10030. This molecule binds to PDGF and blocks its binding to PDGFR-β. In-vitro/in-vivo studies using this compound have shown the effectiveness of its combination with an anti-VEGF agent in preventing the formation of CNV, as well as in the stripping of pericytes from vessels that have already formed, leading to their regression. A phase-I clinical trial that investigates the safety and tolerability of E10030 in humans in combination with ranibizumab or as a monotherapy has been completed.[@b0125] A dose-escalation (0.03 mg, 0.3 mg, 1.5 mg and 3.0 mg) scheme was used. All dose levels were well tolerated with no dose-related toxicities being reported. A significant visual gain (increase in BCVA of ⩾15 letters) was seen in 59% of patients at week 12. Central retinal thickness (CRT), detected by optical coherence tomography (OCT) showed a decrease in thickness at all study visits for all treatment groups. The mean CRT was 395 μm at baseline, 251 μm at week 4, 231 μm at week 8, and 229 μm at week 12. Fluorescein angiography (FA) also demonstrated neovascular regression in all patients from baseline to week 12, with the mean decrease in CNV size being 85.5% compared to baseline.

In conclusion, E10030 showed potential as a possible future therapeutic agent when used in combination with ranibizumab.[@b0130] Following the results of the phase-I study, a phase-II, randomized, double-blind clinical trial was initiated to further evaluate E10030.[@b0135] The study enrolled 449 patients who were randomized in a 1:1:1 ratio into the following groups: 0.3 mg anti-PDGF with 0.5 mg ranibizumab, 1.5 mg anti-PDGF with 0.5 mg ranibizumab, and a sham injection given in conjunction with ranibizumab 0.5 mg. The primary outcome measure of the study was change in BCVA from baseline to week 24. The study results reported that combination therapy of anti-PDGF and ranibizumab was superior to ranibizumab alone, with the combination arm showing 62% improvement in vision. Mean improvement in BCVA was: 10.6 letters, 8.74 letters and 6.52 letters in the 1.5 mg combination group, 0.3 mg combination group and the ranibizumab monotherapy group respectively (*P* = 0.019 for ranibizumab only in comparison with each combination group). The BCVA outcomes in the combination groups were also superior to the monotherapy group when the patients were separately assessed after being subdivided into two groups based on their baseline CRT (CRT \< 316 μm or CRT \> 480 μm).[@b0140]

A phase-III, randomized, double-blind clinical trial has recently been initiated for E10030.[@b0145] The study aims to enroll 622 patients. It will compare the effect of 1.5 mg E10030 intravitreal injection + 0.5 mg ranibizumab intravitreal injection to E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection. The primary outcome measure of the study is the mean change in BCVA from baseline to month 12. Another similar phase-III study has been initiated that plans to compare the combination therapy of E10030 with that of aflibercept or bevacizumab. This study is currently not recruiting.[@b0150] [Table 1](#t0005){ref-type="table"} provides a summary of these trials.

Summary and conclusion {#s0020}
======================

Anti-VEGF monotherapy, has no doubt, proven to be effective in the treatment of AMD. However, the outcomes of patients receiving anti-VEGF therapy has fallen short of expectations for two-thirds of the patients in most clinical trials. Similarly, the long term effects of anti-VEGF therapy have also come under scrutiny in recent times. According to the SEVEN-UP study (Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort), at a mean of 7.3 years after entering the ANCHOR or MARINA trial, BCVA in 34% of study eyes declined by 15 letters or more, with an overall mean decline of 8.6 letters (*P* \< 0.005). Similar limitations in the long term outcomes of patients were also seen in the comparison of AMD treatment trials (CATT) study.[@b0155]

By blocking pericyte's recruitment, survival and maturation, PDGF antagonists inhibit the development and maturation of newly formed vessels, thereby, offering an exciting new treatment option for patients with neovascular AMD.

Recent trials comparing the benefit of combination therapy of ranibizumab and PDGF antagonists to ranibizumab monotherapy have shown superiority of the combination therapy. This might be explained by the fact that both VEGF and PDGF levels increase in neovascularization, and the VEGF is neutralized by anti-VEGF but PDGF continues to work in the absence of PDGF antagonists. In fact, chronic anti-VEGF treatment causes PDGF upregulation, leading to pericyte recruitment and neovascular membrane stabilization.[@b0160] By using PDGF antagonists in combination with VEGF, this vessel protective mechanism may be surpassed to provide a therapeutic option, which treats neovascularization in a more effective manner.

Although PDGF antagonists might have a potential role for treatment in AMD, their role in the treatment of DR might be limited due to the fact that PDGF is required for pericyte retention and recruitment.[@b0165]
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Summary of clinical trials in which PDGF antagonists were evaluated.

  ClinicalTrials.gov Identifier   NCT02214628               NCT01944839                                        NCT00569140                         NCT01089517                                        NCT01940900                                        NCT01940887                                        
  ------------------------------- ------------------------- -------------------------------------------------- ----------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- ------------
  Study design                    Allocation                N/A                                                Randomized                          N/A                                                Randomized                                         Randomized                                         Randomized
  Endpoint classification         Safety study              Safety/efficacy study                              Safety/efficacy study               Safety/efficacy study                              Safety/efficacy study                              Safety/efficacy study                              
  Intervention model              Single group assignment   Parallel assignment                                Single group assignment             Parallel assignment                                Parallel assignment                                Parallel assignment                                
  Masking                         Open label                Double blind                                       Open label                          Double blind                                       Double blind                                       Double blind                                       
  Primary purpose                 Treatment                 Treatment                                          Treatment                           Treatment                                          Treatment                                          Treatment                                          
  Estimated enrollment            100                       622                                                18                                  449                                                622                                                622                                                
  Study period                    96 weeks                  48 weeks                                           48 weeks                            24 weeks                                           24 months                                          48 weeks                                           
  Recruitment status              Recruiting                Recruiting                                         Completed                           Completed                                          Recruiting                                         Not yet recruiting                                 
  Primary outcome measure         Safety                    Change in visual acuity from baseline to Week 48   Ophthalmic dose limiting toxicity   Change in visual acuity from baseline to Week 24   Change in visual acuity from Baseline to Week 48   Change in visual acuity from Baseline to Week 48   
  Estimated completion date       April 2017                July 2016                                          Completed                           Completed                                          July 2016                                          July 2016                                          
